Table 3 Univariate and multivariate analyses of prognostic factors for overall survival in whole-cohort AML patients.
From: HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia
Variables | OS | LFS | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | |
HSPG2 expression (high vs. low) | <0.001 | 4.683 (1.848–11.869) | 0.004 | 3.963 (1.464–7.042) | 0.047 | 2.025 (1.010–3.482) | 0.302 | – |
Age (≥60 vs. <60) | 0.005 | 2.338 (1.296–4.217) | 0.798 | – | 0.214 | 1.465 (0.802–2.675) | – | – |
Sex (male vs. female) | 0.376 | 1.302 (0.726–2.332) | – | – | 0.638 | 1.155 (0.634–2.105) | – | – |
WBC (≥30 vs. <30) | 0.001 | 2.831 (1.563–5.127) | 0.113 | – | 0.004 | 2.550 (1.348–4.824) | 0.026 | 1.969 (1.085–3.571) |
BM Blasts (≥70% vs. <70%) | 0.081 | 1.739 (0.935–3.236) | – | – | 0.771 | 1.110 (0.552–2.232) | – | – |
Treatment regimen | 0.001 | 6.016 (2.146–16.866) | 0.002 | 6.513 (1.969–21.542) | <0.001 | 5.672 (2.254–14.275) | 0.001 | 5.793 (2.064–16.259) |
WT1 mutation | 0.358 | 0.761 (0.425–1.362) | – | – | 0.779 | 1.090 (0.595–1.997) | – | – |
NPM1 mutation | 0.273 | 1.682 (0.663–4.264) | – | – | 0.488 | 1.441 (0.514–4.040) | – | – |
DNMT3A mutation | <0.001 | 4.799 (2.195–10.491) | 0.004 | 3.922 (1.529–10.000) | <0.001 | 6.540 (2.942–14.538) | 0.028 | 6.045 (1.100–5.263) |
C-KIT mutation | 0.445 | 0.574 (0.139–2.380) | – | – | 0.542 | 0.641 (0.154–2.672) | – | – |
FLT3-ITD mutation | 0.089 | 2.443 (0.873–6.838) | – | – | 0.015 | 3.194 (1.250–8.163) | 0.986 | – |
IDH1/2 mutation | 0.100 | 2.689 (0.827–8.804) | – | – | 0.002 | 5.230 (1.836–14.897) | 0.487 | – |
AML1-ETO mutation | 0.026 | 0.200 (0.049–0.827) | – | – | 0.021 | 0.096 (0.013–0.699) | 0.09 | – |
